Hans Biomed Corp
KOSDAQ:042520
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Gaotu Techedu Inc
NYSE:GOTU
|
CN |
|
Nexus AG
XETRA:NXU
|
DE |
|
S
|
Shenzhen Anche Technologies Co Ltd
SZSE:300572
|
CN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (60.2), the stock would be worth ₩20 289.88 (39% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 99.3 | ₩33 450 |
0%
|
| 3-Year Average | 60.2 | ₩20 289.88 |
-39%
|
| 5-Year Average | 25.4 | ₩8 546.04 |
-74%
|
| Industry Average | 16.4 | ₩5 520.73 |
-83%
|
| Country Average | 8.5 | ₩2 877.58 |
-91%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
₩497.1B
|
/ |
Jan 2026
₩5.1B
|
= |
|
|
₩497.1B
|
/ |
Sep 2026
₩21.5B
|
= |
|
|
₩497.1B
|
/ |
Sep 2027
₩37.8B
|
= |
|
|
₩497.1B
|
/ |
Sep 2028
₩55.2B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
H
|
Hans Biomed Corp
KOSDAQ:042520
|
476.4B KRW | 99.3 | -17 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
354.5B USD | 14.1 | 84.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 14 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 12.2 | 19.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.2B USD | 21.1 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 13 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 41 | 38 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.3B AUD | 10.3 | 30.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 5.3 |
| Median | 8.5 |
| 70th Percentile | 15.6 |
| Max | 24 013.5 |
Other Multiples
Hans Biomed Corp
Glance View
Hans Biomed Corp. engages in the manufacture and sale of graft material and silicon products. The company is headquartered in Seoul, Seoul. The company went IPO on 2009-10-09. The firm mainly provides three categories of products: skin-implant materials, bone-implant materials and silicone products. Its skin-implant materials are used for burn treatment and skin graft under the brand names of SureDerm, BellaGen and GPS. Its bone-implant materials include allogeneic bones, xenogenous bones and synthetic bones used in dentistry, orthopedic and others, which are under the brand names of SureFuse, ExFuse and SureOss. Its silicone products are used for treatments of scars and for breast implant and others, which are under the brand names of BellaGel and Scar Clinic. In addition, it provides hair transplanters and others.
